MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1172/jci.insight.95665

Медицинская библиотека · JCI insight · 2017

Early pridopidine treatment improves behavioral and transcriptional deficits in YAC128 Huntington disease mice.

Garcia-Miralles Marta, Geva Michal, Tan Jing Ying, Yusof Nur Amirah Binte Mohammad, Cha Yoonjeong, Kusko Rebecca, Tan Liang Juin, Xu Xiaohong, Grossman Iris, Orbach Aric, Hayden Michael R, Pouladi Mahmoud A

СтатьяПоддержка исследования: вне правительства СШАПеревод пока не подготовлен

Аннотация

Pridopidine is currently under clinical development for Huntington disease (HD), with on-going studies to better characterize its therapeutic benefit and mode of action. Pridopidine was administered either prior to the appearance of disease phenotypes or in advanced stages of disease in the YAC128 mouse model of HD. In the early treatment cohort, animals received 0, 10, or 30 mg/kg pridopidine for a period of 10.5 months. In the late treatment cohort, animals were treated for 8 weeks with 0 mg/kg or an escalating dose of pridopidine (10 to 30 mg/kg over 3 weeks). Early treatment improved motor coordination and reduced anxiety- and depressive-like phenotypes in YAC128 mice, but it did not rescue striatal and corpus callosum atrophy. Late treatment, conversely, only improved depressive-like symptoms. RNA-seq analysis revealed that early pridopidine treatment reversed striatal transcriptional deficits, upregulating disease-specific genes that are known to be downregulated during HD, a finding that is experimentally confirmed herein. This suggests that pridopidine exerts beneficial effects at the transcriptional level. Taken together, our findings support continued clinical development of pridopidine for HD, particularly in the early stages of disease, and provide valuable insight into the potential therapeutic mode of action of pridopidine.

Для цитирования: Garcia-Miralles Marta, Geva Michal, Tan Jing Ying, Yusof Nur Amirah Binte Mohammad, Cha Yoonjeong, Kusko Rebecca, Tan Liang Juin, Xu Xiaohong, Grossman Iris, Orbach Aric, Hayden Michael R, Pouladi Mahmoud A. Early pridopidine treatment improves behavioral and transcriptional deficits in YAC128 Huntington disease mice.. JCI insight. 2017. DOI: 10.1172/jci.insight.95665.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.